Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company developing novel immunotherapies to treat cancer, primarily metastatic breast cancer. Its lead product, Bria-IMT™, is a genetically engineered whole-cell immunotherapy designed to activate the immune system against tumors, often combined with immune checkpoint inhibitors. The company also develops personalized off-the-shelf immunotherapies for multiple cancers. BriaCell relies on third-party manufacturing and targets oncologists and cancer treatment centers globally.
This description was generated via AI from an annual report. Updated about 1 year ago.